Logo image of CRNX

CRINETICS PHARMACEUTICALS IN (CRNX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRNX - US22663K1079 - Common Stock

54.9 USD
+0.59 (+1.09%)
Last: 1/14/2026, 11:04:06 AM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CRNX. CRNX was compared to 190 industry peers in the Pharmaceuticals industry. CRNX has a great financial health rating, but its profitability evaluates not so good. CRNX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CRNX had negative earnings in the past year.
  • In the past year CRNX has reported a negative cash flow from operations.
  • In the past 5 years CRNX always reported negative net income.
  • CRNX had a negative operating cash flow in each of the past 5 years.
CRNX Yearly Net Income VS EBIT VS OCF VS FCFCRNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • CRNX has a Return On Assets (-35.38%) which is comparable to the rest of the industry.
  • CRNX has a Return On Equity of -39.46%. This is comparable to the rest of the industry: CRNX outperforms 56.32% of its industry peers.
Industry RankSector Rank
ROA -35.38%
ROE -39.46%
ROIC N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
CRNX Yearly ROA, ROE, ROICCRNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CRNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNX Yearly Profit, Operating, Gross MarginsCRNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

  • CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CRNX has more shares outstanding
  • CRNX has more shares outstanding than it did 5 years ago.
  • CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRNX Yearly Shares OutstandingCRNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRNX Yearly Total Debt VS Total AssetsCRNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • An Altman-Z score of 23.18 indicates that CRNX is not in any danger for bankruptcy at the moment.
  • CRNX has a Altman-Z score of 23.18. This is amongst the best in the industry. CRNX outperforms 87.89% of its industry peers.
  • CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.18
ROIC/WACCN/A
WACC9.41%
CRNX Yearly LT Debt VS Equity VS FCFCRNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • CRNX has a Current Ratio of 15.12. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of CRNX (15.12) is better than 84.74% of its industry peers.
  • A Quick Ratio of 15.12 indicates that CRNX has no problem at all paying its short term obligations.
  • CRNX's Quick ratio of 15.12 is amongst the best of the industry. CRNX outperforms 85.26% of its industry peers.
Industry RankSector Rank
Current Ratio 15.12
Quick Ratio 15.12
CRNX Yearly Current Assets VS Current LiabilitesCRNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

  • CRNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.45%.
  • Looking at the last year, CRNX shows a very strong growth in Revenue. The Revenue has grown by 47.74%.
  • Measured over the past years, CRNX shows a decrease in Revenue. The Revenue has been decreasing by -2.68% on average per year.
EPS 1Y (TTM)-21.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.75%
Revenue 1Y (TTM)47.74%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 22.31% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 273.06% on average over the next years. This is a very strong growth
EPS Next Y-37.76%
EPS Next 2Y-20.69%
EPS Next 3Y-0.83%
EPS Next 5Y22.31%
Revenue Next Year224.94%
Revenue Next 2Y482.25%
Revenue Next 3Y384.21%
Revenue Next 5Y273.06%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRNX Yearly Revenue VS EstimatesCRNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
CRNX Yearly EPS VS EstimatesCRNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 20 30 40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • CRNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRNX Price Earnings VS Forward Price EarningsCRNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNX Per share dataCRNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.69%
EPS Next 3Y-0.83%

More info and screens

0

5. Dividend

5.1 Amount

  • CRNX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (1/14/2026, 11:04:06 AM)

54.9

+0.59 (+1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners115.45%
Inst Owner Change-0.04%
Ins Owners1.71%
Ins Owner Change3.94%
Market Cap5.21B
Revenue(TTM)1.53M
Net Income(TTM)-423.10M
Analysts83.64
Price Target81.75 (48.91%)
Short Float %15.48%
Short Ratio11.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.77%
Min EPS beat(2)-9.79%
Max EPS beat(2)-7.76%
EPS beat(4)1
Avg EPS beat(4)-5.74%
Min EPS beat(4)-9.79%
Max EPS beat(4)2.94%
EPS beat(8)1
Avg EPS beat(8)-6.07%
EPS beat(12)1
Avg EPS beat(12)-6.18%
EPS beat(16)2
Avg EPS beat(16)-6.92%
Revenue beat(2)1
Avg Revenue beat(2)310.54%
Min Revenue beat(2)-61.44%
Max Revenue beat(2)682.52%
Revenue beat(4)2
Avg Revenue beat(4)202.6%
Min Revenue beat(4)-100%
Max Revenue beat(4)682.52%
Revenue beat(8)3
Avg Revenue beat(8)91.58%
Revenue beat(12)7
Avg Revenue beat(12)151.74%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.44%
EPS NY rev (1m)-0.06%
EPS NY rev (3m)-5.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.12%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-0.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3393.79
P/FCF N/A
P/OCF N/A
P/B 4.86
P/tB 4.86
EV/EBITDA N/A
EPS(TTM)-4.53
EYN/A
EPS(NY)-5.4
Fwd EYN/A
FCF(TTM)-3.75
FCFYN/A
OCF(TTM)-3.69
OCFYN/A
SpS0.02
BVpS11.3
TBVpS11.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.38%
ROE -39.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 171.91%
Cap/Sales 412.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.12
Quick Ratio 15.12
Altman-Z 23.18
F-Score3
WACC9.41%
ROIC/WACCN/A
Cap/Depr(3y)244.79%
Cap/Depr(5y)160.44%
Cap/Sales(3y)173.94%
Cap/Sales(5y)166.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.75%
EPS Next Y-37.76%
EPS Next 2Y-20.69%
EPS Next 3Y-0.83%
EPS Next 5Y22.31%
Revenue 1Y (TTM)47.74%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%N/A
Revenue Next Year224.94%
Revenue Next 2Y482.25%
Revenue Next 3Y384.21%
Revenue Next 5Y273.06%
EBIT growth 1Y-55.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.55%
EBIT Next 3Y-3.6%
EBIT Next 5YN/A
FCF growth 1Y-113.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-114.54%
OCF growth 3YN/A
OCF growth 5YN/A

CRINETICS PHARMACEUTICALS IN / CRNX FAQ

What is the ChartMill fundamental rating of CRINETICS PHARMACEUTICALS IN (CRNX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRNX.


Can you provide the valuation status for CRINETICS PHARMACEUTICALS IN?

ChartMill assigns a valuation rating of 0 / 10 to CRINETICS PHARMACEUTICALS IN (CRNX). This can be considered as Overvalued.


What is the profitability of CRNX stock?

CRINETICS PHARMACEUTICALS IN (CRNX) has a profitability rating of 1 / 10.